drugset / Trial / NCT02623231

The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

NCT02623231

Phase 2/3 Unknown 100 enrolled Tel-Aviv Sourasky Medical Center
RandomizedParallel-groupDouble-blindSupportive care

Summary

Testing the effect of providing an antidepressant and anxiety-type escitalopram for patients with glioblastoma on patient's quality of life including the effect of treatment on mood and cognition during treatment.Two subgroups will fill questionnaires : * Questionnaire mini mental state exam (mmse) which is the maximum score of 30. A score of below 24 indicates a flaw in the level of dementia * Questionnaire depression / mood PHQ9P(Pa t i e n t H e a l t h Qu e s t i o n n a i r e - 9) * The M. D. Anderson Symptom Inventory (MDASI) * Evaluation of the hospital situation awareness (clinical assessment and questionnaire) * Cognitive assessment which will be carried out by the Department neuropsychological and include: * Executive function (Stroop) * Abstract Reasoning (similarities) * -Auditory and Spatial Attention (Digit span, Spatial span) visual memory and remembering Literature * Memory function - visual and auditory (ROCF, RAVLT) * Language function: Naming and verbal fluency * Mindstreems Neurotrax

Timeline

Start
2015-12
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 20 mg